Palócz E, Kerkovits G
Ther Hung. 1989;37(4):220-4.
The authors used Captopril (Tensiomin, Egis Pharmaceuticals, Budapest) therapy in seven patients suffering from chronic heart failure of ischaemic etiology. As controls, seven patients with dilated cardiomyopathy were involved in the study. All 14 patients received digitalis, diuretic, and isosorbide dinitrate therapy but their condition aggrevated in spite of the therapy. The above-mentioned therapy was completed with daily 3 x 12.5-mg or 3 x 25-mg oral Captopril doses. Significant improvement proved by chest X-ray, echocardiography, and clinical data was observed in four of the ischaemic heart disease patients and three of the dilated cardiomyopathic patients. In other two patients each the improvement was temporary, after 6 weeks of therapy deterioration of the disease was observed. Notable change was not observed in response to Captopril in one ischaemic and two primary cardiomyopathic patients. Tensiomin may be considered as one of the drugs of primary importance in the treatment of chronic congestive heart failure.
作者对7例缺血性病因的慢性心力衰竭患者使用了卡托普利（开博通，匈牙利埃吉斯制药公司）进行治疗。作为对照，7例扩张型心肌病患者参与了该研究。所有14例患者均接受了洋地黄、利尿剂和硝酸异山梨酯治疗，但尽管进行了治疗，他们的病情仍加重。上述治疗方案中加用了每日3次、每次12.5毫克或3次、每次25毫克的口服卡托普利剂量。通过胸部X光、超声心动图和临床数据证实，4例缺血性心脏病患者和3例扩张型心肌病患者有显著改善。另外两名患者的改善是暂时的，治疗6周后病情恶化。1例缺血性心脏病患者和2例原发性心肌病患者对卡托普利无明显反应。开博通可被视为治疗慢性充血性心力衰竭的主要药物之一。
